The association of gene polymorphism and susceptibility to hepatocellular carcinoma (HCC) has been widely studied in recent years. Gene mutations are closely related to HCC. Understanding and measuring the gene mutations are useful to reduce the incidence of HCC and improve its prognosis.
C hronic hepatitis B virus (HBV) infection is related to hepatocellular carcinoma (HCC), but the mechanism remains unclear. A great deal of researches has been conducted to explore the relationship between gene polymorphism and HCC in recent years. Many studies indicated that gene mutations and HCC are closely related. These researches mostly are carried out in Asia, and the subjects, size and results are prominent especially in China. They put forward a new idea for diagnosis and treatment of HCC, and provide a new direction for further research on how to reduce the risk of liver cancer, and how to treat chronic hepatitis B and liver cancer. If HCC susceptible populations were screened in time, and were given intervention and preventive measures early, the incidence of HCC would be expected to reduce.
STAT4 AND LEUKOCYTE ANTIGEN GENE MUTATION AND HCC
S TAT 4 ( s i g n a l t r a n s d u c e r a n d a c t i v a t o r o f transcription factor 4) is a signal transducer and activator of transcription factor, and HLA-DQ is a leukocyte antigen DQ gene. Now, it's obviously that they are involved in the pathogenesis of HCC. In a Chinese study, 11 799 blood cell DNA samples of independent people with chronic hepatitis B in 7 areas in China were collected by Human leukocyte antigen DP-DQ gene mutation has effects on the clearance of HBV and occurrence of HCC. A recent GWAS research found that HLA-DP (rs3077 and rs9277535) and HLA-DQ (rs2856718 and rs7453920) were associated with HCC in patients with chronic HBV infection. Hu et al studied 1 300 cases of HCC patients with positive HBV, 1 344 cases of HBV carriers, 1 344 cases of patients with spontaneous HBV clearance, and found that HLA-DP rs9277535, HLA-DQ rs7453920 and rs2856718 could affect the clearance of HBV.
2 Besides, HLA-DP rs3077 showed significant susceptibility to persistent infection of HBV and occurrence of HCC. The correlation between HLAⅡ gene and HCC has certain differences in different nations and races. DOI: 10.1515 DOI: 10. /ii-2017 There was a significant correlation between HLAⅡ DRB1*04, DQB1*02 and HCC in Egypt. HLAⅡ DRB1*04 and DQB1*02 were risk factors of HCC, while DQB1*06 might be a protective gene. 3 Jin et al found that the frequency of HLA-DRB1*140101 allele in HCC patients was significant higher than that of non-cancer group. 4 Patients with HLA-DRB1*140101 allele had a higher cumulative incidence of HCC than patients without it in the 2th, 4th, 6th year. They drew a conclusion that HLA-DRB1*140101 was a potential risk factor for the patients with chronic HBV infection to deteriorate into HCC.
P53 AND MDM2 POLYMORPHISMS AND HCC
The p53 (tumor suppressor gene) signal pathway is a powerful barrier for the progression of tumors. p53 has 2 SNPs loci, p53 codon 72Arg (arginine) 72Pro (proline) and MDM2 (murine double minute 2) SNP309 (T > G, deoxythymidine > deoxyguanosine), which can induce dysfunction of p53. But the risk of two SNPs in HCC is not consistent. MDM2, one of the oncogene, is a ubiquitin protein ligase, which is composed of 698 adenine, 491 cytosine, 541 guanine, 624 thymine. It consists of five different types, MDM2 a, b, c, d and e. It is not only one of the target gene transcriptionally regulated by p53, but also an important regulative factor of p53. Yang et al studied 350 cases of HCC, 230 cases of patients without HCC, 96 cases of healthy controls. The results showed that p53 Pro/Pro and MDM2 G/G had a significant correlation with HCC (P = 0.047), and they were the independent factors influencing the recurrence and survival of HCC (P < 0.05). 5 Yang et al also found that the patients with p53 Pro/Pro and MDM2 G/G genotype simultaneously had poorer prognosis than those with other genotype. The DFS (disease-free survival) and OS (overall survival) were significantly different. Patients with p53 Pro/Pro and MDM2 G/G genotype simultaneously had poorer prognosis compared with those with other genotypes in A stage (P < 0.05). Thus, the combined Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC. A case-control study in Turkey suggested that the p53 Pro/Pro homozygotes, especially in male patients with HBV infection was the susceptible gene to HCC. 6 South Korean scholars pointed out that MDM2 SNP 309 and p53Arg72Pro were associated with early HCC in patients with chronic HBV infection. 7 SNP 309 T > G at MDM2 promoter can affect expression of MDM2 protein and tumorigenesis. Logistic regression analysis showed that HBV-related HCC patients had significant different deletion of MDM2 SNP 309 compared with healthy controls or non-HCC patients with HBV infection, and also revealed that patients with G allele had a higher incidence of HCC than patients with T allele. 8, 9 THE MIRNA POLYMORPHISM AND HCC MiRNAs (micro RNAs) 371-373 is originated from the transcription of former miRNA. There is upregulation of miRNA in HBV-related HCC patients, and miRNA can regulate HBV infection. Kwak et al used TaqMan probe to study the relationship of primary miRNAs (pri-miRNAs) 371-373 polymorphism with occurrence of HCC and clearance of HBV. The results showed that among chronic carriers and liver cirrhosis patients, the A allele of rs3859501 and the haplotype primiRNAs-371-373_ht2 were more protective to HCC than other genotypes and haplotypes.
10
One study found that pri-miRNA-196a functional polymorphism could lead to susceptibility to HCC. MiRNAs are non-protein coding RNAs. Abnormal expression and structural changes of miRNA are involved in the occurrence and development of cancer. The SNP in pri-miRNA can change the miRNA's processing, expression and/or binding to target miRNA, then cause tumor. Recent research indicated that miRNA-196 a2 rs11614913 (C→T) could change the expression of miRNA-196a2 and bind to the target miRNA. The results showed that miRNA-196-a2 rs11614913 could increase the risk of HCC (especially in female patients with HBV infection). It was identified as a susceptibility gene of HCC.
11, 12

DNA DOUBLE STRAND BREAK REPAIR GENE XRCC5 POLYMORPHISMS AND HCC
XRCC (X-ray repair cross complementing) genes contain seven kinds. As a member of RAD51 family, it is the repair gene of DNA double strand breaks. DNA damages caused by environmental risk factors are not repaired accurately, which induces chromosomal aberration, genomic instability and occurrence of HCC. XRCC5 gene mutation may lead to susceptibility to HCC. Studies had found that XRCC5 rs16855458 could significantly reduce the risk of HCC, while XRCC5 rs9288516 could significantly increase the risk of HCC, and the role of them was more significant in patients with HBV infection than patients without HBV infection. Haplotype analysis showed that XRCC5 gene had one risk haplotype "AAATC" and two protective haplotypes "GGGTT", and the latter reduced the risk of HCC. 13 So mutation of XRCC5 gene may play a role in susceptibility to HCC.
A research found that XRCC1 gene C.1161 G > A and C.1799 C > G were associated with increased risk of HCC in Chinese population using PCR-RFLP. As for the C.1161G > A, the AA genotype was statistically associated with the increased risk of HCC compared to GG wild genotype. As for the C.1779C > G, the risk of HCC was significantly higher for GG genotype compared to CC wild genotype.
14 A study on the relationship of the XRCC4 coding region polymorphisms with Aspergillus flavus B1 associated HCC indicated that XRCC4 rs28383151 AA genotype increased the risk of HCC. It may be a potential risk gene, and can be used as a biochemical marker of HCC prognosis.
15
CORTICOTROPIN-RELEASING HORMONE RECEPTOR 2 GENE INTRON POLYMORPHISM AND HCC
Corticotropin-releasing hormone receptor 2 (CRHR2) works in the central and peripheral nervous system. Urocortin (Ucns) and corticotropin releasing hormone (CRH), as the ligand of CRHR2, can mediate inflammatory reaction and inhibit angiogenesis. The recent study found CRHR2 expresseed in many human cancer cells, and was found in the patients with chronic hepatitis C virus infection. CRHR2 gene rs2267716 polymorphism is related to HCC susceptibility. Using PCR-LDR (ligation detection reaction), Gu et al studied 364 cases of HBV-related HCC, 196 cases of non-HCC patients with HBV infection and 404 cases of healthy controls, and found that significant differences of rs2267716 allele were detected between HBV-related HCC patients and healthy controls or non-HCC patients with HBV infection.
16 CRHR2 gene rs2267716 polymorphism may increase the risk of developing HCC. 
MDR1 GENE POLYMORPHISM AND HCC
CONCLUSIONS
Numerous gene polymorphisms are associated with the occurrence, development and prognosis of HCC, but most of these gene mutations are not unique to HCC, and they also can occur in many tumors of other parts of the body, so their specificity is poor. Most of the current studies have small number of cases. It requires large scale, multi-country, multi-ethnic and multi-region studies to further determine the clinical value of these gene polymorphisms. At present, the role of these gene polymorphisms in the diagnosis and treatment of HCC needs further study. As time goes on, more gene polymorphisms associated with HCC will be identified. We expect to have a new breakthrough in the prevention and treatment of HCC with the more understanding to the pathogenesis of HCC.
